...A. A good example of that would be the recent divestiture of our ENT business in Acclarent, which we also closed in the last quarter. B. If you look back to 2017, we grew 1.5%. C. And through 2007 to 2023 when we grew just under 8%. D. And I know you compare us with everyone, but there are a few $30 billion med tech companies. E. We're lucky we operate in markets that represent about $1 billion -- sorry, $100 billion, all growing at a weighted average of about 5% to 7%. F. And another follow-up, just -- I believe you mentioned the high growth portfolio mix has grown from around 20% to about 50%. G. Let's think about the $22 billion that we've invested in M&A. It's really been focused on choiceful decisions in areas, number one, of significant unmet need, areas of high growth where we have differentiation and healthy margins. H. It's not only the largest category in med tech, $60 billion, by the way, growing at a weighted average of roughly 8%. I. That's a $5 billion incremental growth just...
